Published in Arch Neurol on April 01, 2009
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat Med (2011) 2.69
Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Sci Transl Med (2012) 2.14
Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. J Exp Med (2010) 1.70
Interleukin-2/interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation. Ann Neurol (2011) 1.67
An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells. J Immunol (2010) 1.57
Organ-specific features of natural killer cells. Nat Rev Immunol (2011) 1.48
Daclizumab therapy for multiple sclerosis. Neurotherapeutics (2013) 1.33
The cytokine milieu in the interplay of pathogenic Th1/Th17 cells and regulatory T cells in autoimmune disease. Cell Mol Immunol (2010) 1.21
Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis. Clin Dev Immunol (2011) 1.18
Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis. J Immunol (2011) 1.18
Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis. Nat Rev Neurol (2013) 1.13
Retracted Multiple sclerosis: the role of cytokines in pathogenesis and in therapies. Int J Mol Sci (2012) 1.11
Application of IL-2 therapy to target T regulatory cell function. Trends Immunol (2012) 1.11
The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment. Handb Clin Neurol (2014) 1.11
Natural killer cells in human autoimmune disorders. Arthritis Res Ther (2013) 1.10
Intrathecal effects of daclizumab treatment of multiple sclerosis. Neurology (2011) 1.08
Current landscape for T-cell targeting in autoimmunity and transplantation. Immunotherapy (2011) 1.02
Therapeutic strategies in childhood multiple sclerosis. Ther Adv Neurol Disord (2010) 1.01
Treatment of multiple sclerosis: current concepts and future perspectives. J Neurol (2011) 0.98
Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis. Ann Clin Transl Neurol (2015) 0.96
Subsets of human natural killer cells and their regulatory effects. Immunology (2014) 0.93
The contribution of immune and glial cell types in experimental autoimmune encephalomyelitis and multiple sclerosis. Mult Scler Int (2014) 0.93
Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation. Proc Natl Acad Sci U S A (2016) 0.92
New approaches in the management of multiple sclerosis. Drug Des Devel Ther (2010) 0.92
Monoclonal antibodies in treatment of multiple sclerosis. Clin Exp Immunol (2014) 0.91
The role of natural killer cells in multiple sclerosis and their therapeutic implications. Front Immunol (2013) 0.91
Current and future immunomodulation strategies to restore tolerance in autoimmune diseases. Cold Spring Harb Perspect Biol (2012) 0.91
Multiple sclerosis treatment and infectious issues: update 2013. Clin Exp Immunol (2014) 0.90
The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis. Ther Adv Neurol Disord (2014) 0.89
The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord (2013) 0.87
Natural killer cells and their receptors in multiple sclerosis. Brain (2012) 0.87
Novel targeted therapies for autoimmunity. Curr Opin Immunol (2009) 0.87
Monoclonal antibody therapy in multiple sclerosis: Paradigm shifts and emerging challenges. MAbs (2010) 0.86
Natural killer cells as indispensable players and therapeutic targets in autoimmunity. Autoimmunity (2010) 0.86
Polymorphisms in the IL2, IL2RA and IL2RB genes in multiple sclerosis risk. Eur J Hum Genet (2010) 0.83
Cutaneous adverse events in multiple sclerosis patients treated with daclizumab. Neurology (2016) 0.83
Tolerogen-induced interferon-producing killer dendritic cells (IKDCs) protect against EAE. J Autoimmun (2011) 0.83
A complex role of herpes viruses in the disease process of multiple sclerosis. PLoS One (2014) 0.82
Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications. Neurotherapeutics (2016) 0.81
CNS vasculitis in a patient with MS on daclizumab monotherapy. Neurology (2013) 0.81
What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis? Int J Mol Sci (2012) 0.81
Emerging immunopharmacological targets in multiple sclerosis. J Neurol Sci (2015) 0.81
Patients with MS under daclizumab therapy mount normal immune responses to influenza vaccination. Neurol Neuroimmunol Neuroinflamm (2016) 0.81
Examination of the role of magnetic resonance imaging in multiple sclerosis: A problem-orientated approach. Ann Indian Acad Neurol (2009) 0.80
3,3'-diindolylmethane ameliorates experimental autoimmune encephalomyelitis by promoting cell cycle arrest and apoptosis in activated T cells through microRNA signaling pathways. J Pharmacol Exp Ther (2014) 0.79
Recent developments in multiple sclerosis therapeutics. BMC Med (2009) 0.79
Novel composite MRI scale correlates highly with disability in multiple sclerosis patients. Mult Scler Relat Disord (2015) 0.78
Emerging therapies for treatment of multiple sclerosis. J Inflamm Res (2010) 0.78
Cytokine Therapies in Neurological Disease. Neurotherapeutics (2016) 0.78
New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come. J Cent Nerv Syst Dis (2012) 0.77
Anti-CD25 monoclonal antibody Fc variants differentially impact regulatory T cells and immune homeostasis. Immunology (2016) 0.77
Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes. Ther Adv Neurol Disord (2015) 0.76
CD300c is uniquely expressed on CD56(bright) Natural Killer Cells and differs from CD300a upon ligand recognition. Sci Rep (2016) 0.76
Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis. Biologics (2016) 0.75
Diagnosis and Management of Multiple Sclerosis in Children. Iran J Child Neurol (2016) 0.75
Regulatory Functions of Natural Killer Cells in Multiple Sclerosis. Front Immunol (2016) 0.75
Monoclonal antibodies in the treatment of multiple sclerosis: emergence of B-cell-targeted therapies. Br J Pharmacol (2017) 0.75
Recent advances in the treatment of multiple sclerosis. J Exp Pharmacol (2010) 0.75
Daclizumab high-yield process in the treatment of relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord (2016) 0.75
Review of daclizumab and its therapeutic potential in the treatment of relapsing-remitting multiple sclerosis. Drug Des Devel Ther (2013) 0.75
Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology (1983) 40.64
PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS. Ann N Y Acad Sci (1965) 6.34
Interferons alpha and beta as immune regulators--a new look. Immunity (2001) 4.75
Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A (2006) 4.26
The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler (1999) 3.71
Method for quantification of brain, ventricular, and subarachnoid CSF volumes from MR images. J Comput Assist Tomogr (1992) 3.62
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci U S A (2004) 2.37
Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology (2007) 1.63
Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol (2004) 1.40
Clinical scales for multiple sclerosis. J Neurol Sci (1996) 1.39
Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. Neurol Sci (2007) 1.39
Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells. Brain (2008) 1.34
The role of natural killer cells in curbing neuroinflammation. J Neuroimmunol (2007) 1.29
Magnetic resonance imaging measures of brain atrophy in multiple sclerosis. J Magn Reson Imaging (2006) 1.14
Human NK cells inhibit cytomegalovirus replication through a noncytolytic mechanism involving lymphotoxin-dependent induction of IFN-beta. J Immunol (2005) 1.04
NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis. Rheumatol Int (2008) 1.02
Spotlight on anti-CD25: daclizumab in MS. Int MS J (2008) 0.94
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol (2005) 24.22
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Immunology of multiple sclerosis. Annu Rev Immunol (2005) 9.08
IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity (2002) 6.10
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A (2005) 5.21
Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol (2007) 4.87
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A (2004) 4.70
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet (2013) 4.62
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature (2012) 4.33
Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A (2006) 4.26
TCR ligand discrimination is enforced by competing ERK positive and SHP-1 negative feedback pathways. Nat Immunol (2003) 4.17
Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity (2008) 3.67
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell (2012) 3.00
Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat Biotechnol (2003) 2.80
A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat Med (2011) 2.69
Comparison of endoscopic ultrasonography and multidetector computed tomography for detecting and staging pancreatic cancer. Ann Intern Med (2004) 2.44
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci U S A (2004) 2.37
Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med (2005) 2.30
A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res (2007) 2.24
Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. Proc Natl Acad Sci U S A (2003) 2.20
Superior T memory stem cell persistence supports long-lived T cell memory. J Clin Invest (2013) 2.06
Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J Immunol (2005) 2.01
Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. Annu Rev Neurosci (2002) 1.99
Structure of a human autoimmune TCR bound to a myelin basic protein self-peptide and a multiple sclerosis-associated MHC class II molecule. EMBO J (2005) 1.98
IL-15/IL-15Ralpha-mediated avidity maturation of memory CD8+ T cells. Proc Natl Acad Sci U S A (2004) 1.92
Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. Clin Cancer Res (2010) 1.92
FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma. Blood (2011) 1.86
Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action. J Immunol (2008) 1.85
Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005. Biol Blood Marrow Transplant (2005) 1.81
Using peripheral blood mononuclear cells to determine a gene expression profile of acute ischemic stroke: a pilot investigation. Circulation (2005) 1.79
Development of biomarkers in multiple sclerosis. Brain (2004) 1.78
CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP. Blood (2010) 1.77
The IL-15/IL-15Ralpha on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells. Proc Natl Acad Sci U S A (2007) 1.76
IL-15 as a mediator of CD4+ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis. Proc Natl Acad Sci U S A (2008) 1.72
Identification of a novel risk locus for multiple sclerosis at 13q31.3 by a pooled genome-wide scan of 500,000 single nucleotide polymorphisms. PLoS One (2008) 1.72
Molecular tracking of antigen-specific T cell clones in neurological immune-mediated disorders. Brain (2003) 1.71
The OSCAR-IB consensus criteria for retinal OCT quality assessment. PLoS One (2012) 1.67
Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun (2003) 1.66
Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci (2011) 1.64
Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. Proc Natl Acad Sci U S A (2012) 1.64
Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood (2004) 1.62
Effects of interferon beta-1b on black holes in multiple sclerosis over a 6-year period with monthly evaluations. Arch Neurol (2005) 1.60
Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid. Proc Natl Acad Sci U S A (2007) 1.60
Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. Hum Mol Genet (2003) 1.59
Plasmid-encoded interleukin-15 receptor alpha enhances specific immune responses induced by a DNA vaccine in vivo. Hum Gene Ther (2009) 1.57
Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis. J Immunol (2004) 1.56
Heterogeneity in response to interferon beta in patients with multiple sclerosis: a 3-year monthly imaging study. Arch Neurol (2008) 1.56
Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent. J Natl Cancer Inst (2004) 1.55
ITK and IL-15 support two distinct subsets of CD8+ T cells. Proc Natl Acad Sci U S A (2006) 1.55
Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis. Sci Transl Med (2013) 1.54
EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies. Clin Cancer Res (2009) 1.53
Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain (2006) 1.53
Degenerate TCR recognition and dual DR2 restriction of autoreactive T cells: implications for the initiation of the autoimmune response in multiple sclerosis. Eur J Immunol (2008) 1.51
Micro-magnetic resonance lymphangiography in mice using a novel dendrimer-based magnetic resonance imaging contrast agent. Cancer Res (2003) 1.43
Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain (2003) 1.43
Clinical nurse specialists and the practice of community nurses. J Adv Nurs (2006) 1.42
Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. Arch Neurol (2009) 1.42
Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primates. Blood (2010) 1.41
Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene. Proc Natl Acad Sci U S A (2006) 1.39
Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. JAMA (2011) 1.38
Survival adjustment of mature dendritic cells by IL-15. Proc Natl Acad Sci U S A (2005) 1.37
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol (2010) 1.37
EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. J Exp Med (2008) 1.33
Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood (2006) 1.33
JC virus granule cell neuronopathy and GCN-IRIS under natalizumab treatment. Ann Neurol (2013) 1.29
Antibody-mediated blockade of IL-15 reverses the autoimmune intestinal damage in transgenic mice that overexpress IL-15 in enterocytes. Proc Natl Acad Sci U S A (2009) 1.28
Notch signaling contributes to proliferation and tumor formation of human T-cell leukemia virus type 1-associated adult T-cell leukemia. Proc Natl Acad Sci U S A (2010) 1.27
Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res (2002) 1.25
IL-2 and IL-15 receptor alpha-subunits are coexpressed in a supramolecular receptor cluster in lipid rafts of T cells. Proc Natl Acad Sci U S A (2004) 1.25
Retinal damage in multiple sclerosis disease subtypes measured by high-resolution optical coherence tomography. Mult Scler Int (2012) 1.24
Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome. Brain (2011) 1.22
Digital droplet PCR (ddPCR) for the precise quantification of human T-lymphotropic virus 1 proviral loads in peripheral blood and cerebrospinal fluid of HAM/TSP patients and identification of viral mutations. J Neurovirol (2014) 1.22
Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability. Blood (2009) 1.21
Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain (2010) 1.21
T lymphocyte priming by neutrophil extracellular traps links innate and adaptive immune responses. J Immunol (2012) 1.21
Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc Natl Acad Sci U S A (2003) 1.18
Comparison of dendrimer-based macromolecular contrast agents for dynamic micro-magnetic resonance lymphangiography. Magn Reson Med (2003) 1.18
Structure of a TCR with high affinity for self-antigen reveals basis for escape from negative selection. EMBO J (2011) 1.17
Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis. Eur J Immunol (2011) 1.17
Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch Neurol (2009) 1.16
A powerful combination: the use of positional scanning libraries and biometrical analysis to identify cross-reactive T cell epitopes. Mol Immunol (2004) 1.15
Relationship of cortical atrophy to fatigue in patients with multiple sclerosis. Arch Neurol (2010) 1.13
Non-ampullary duodenal adenocarcinoma: factors important for relapse and survival. J Surg Oncol (2009) 1.12
Epstein-barr virus: environmental trigger of multiple sclerosis? J Virol (2007) 1.11
Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer. Proc Natl Acad Sci U S A (2009) 1.11
The value of animal models for drug development in multiple sclerosis. Brain (2006) 1.11
Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. Cancer Res (2003) 1.11